Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnimalcare Grp Regulatory News (ANCR)

Share Price Information for Animalcare Grp (ANCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 217.00
Bid: 214.00
Ask: 220.00
Change: 0.00 (0.00%)
Spread: 6.00 (2.804%)
Open: 217.00
High: 217.00
Low: 217.00
Prev. Close: 217.00
ANCR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

23 Jul 2020 07:00

RNS Number : 8176T
Animalcare Group PLC
23 July 2020
 

ANIMALCARE GROUP PLC

(the "Company" or the "Group")

Trading update and Notice of Results

 

 

23 July 2020. Animalcare Group plc (AIM: ANCR), the international animal health business, provides the following unaudited trading update for the six months ended 30 June 2020 ahead of publishing its interim results on 29 September 2020.

 

Trading overview

The Group is pleased to report a resilient first half performance despite the disruption due to COVID-19. While trading for the first half was down on the prior year, our overall performance was at the higher end of the Company's range of scenario modelling, helping maintain our strong financial position and focus on our growth strategy.

 

Revenue for the period declined by 4.4% to £34.5 million (4.8% at constant exchange rates) reflecting the disruption to veterinary activity across Europe caused by the pandemic. This effect was largely observed within our Companion Animal portfolio during Q2 due to public health measures restricting veterinary activity, offset in part by strong growth in Production Animals. Evidence of a return to more normal customer activity in some markets was visible towards the end of the first half and has continued to develop post period-end. However, uncertainty about the shape and extent of a recovery in demand prevails.

 

Underlying EBITDA margin is expected to be in line with the first half of 2019 as the Company benefits from the impact of cost efficiencies generated during 2019 together with decisive action to realign SG&A spend during the pandemic. This has not prevented the Company from investing in drivers of future growth including new product launches, pipeline projects and business development opportunities.

 

As part of our growth strategy, we are committed to strengthening our balance sheet and improving our cash generation to create capacity to invest in future growth. This goal continues to guide us over the long term. As at 30 June 2020 our net debt stood at £18.1 million, broadly in line with the year ended 31 December 2019. As anticipated, cash conversion in the first half was lower than the prior period, largely due to an increase in working capital, in particular inventory, due to the impact of COVID-19 together with strategic stock build of certain key brands. We expect cash conversion to improve during H2 as our stock profile returns to more normal levels. 

 

Jenny Winter, Chief Executive Officer commented: "Given the unprecedented disruption to the animal health sector in recent months, our resilient performance highlights our organisational agility and the strength of the platform we have built in recent years. Uncertainty remains over the shape and speed of the recovery in the second half and we continue to adapt to the evolving needs of our veterinary customers. Huge credit must go to our employees whose skills and commitment have continued to drive the Group forward during this difficult period.

 

"Despite the challenges, our focus on our growth strategy is as strong as ever and we continue to invest in our pipeline, new products and the pursuit of business development opportunities."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

 

 

For further information, please contact:

Animalcare Group plc

 

Jenny Winter, Chief Executive Officer

Chris Brewster, Chief Financial Officer

Media relations

+44 (0)1904 487 687 

 

communications@animalcaregroup.com

 

 

Panmure Gordon (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley/Emma Earl

Corporate Broking

James Stearns

+44 (0)20 7886 2500

 

About Animalcare www.animalcaregroup.com

Animalcare Group plc is a UK AIM-listed international veterinary sales and marketing organisation. Animalcare operates in seven countries and exports to approximately 32 countries in Europe and a further 16 worldwide. The Group is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBIGDRSXDDGGD
Date   Source Headline
11th Apr 20242:57 pmRNSSale of equity in STEM Animal Health Inc.
9th Apr 20248:22 amRNSInvestor presentation via Investor Meet Company
9th Apr 20247:00 amRNSPreliminary Unaudited Full Year Results 2023
28th Feb 20247:00 amRNSDisposal of Identicare Ltd
29th Jan 202410:27 amRNSNotification of Major Holding
25th Jan 20247:00 amRNSTrading Update and Notice of 2023 FY Results
9th Nov 20232:01 pmRNSNotification of Major Holding
1st Nov 202311:38 amRNSNotification of Major Holding
12th Oct 20231:28 pmRNSExercise of Options and Total Voting Rights
5th Oct 20237:00 amRNSPDMR Dealing – Dividend Reinvestment Plan
2nd Oct 20234:42 pmRNSNotification of Major Holding
26th Sep 20237:00 amRNSInterim Results for six months ended 30 June 2023
19th Sep 20239:04 amRNSNotification of Major Holding
18th Sep 20236:23 pmRNSNotification of Major Holding
27th Jul 20237:00 amRNSHalf year Trading Update and Notice of Interims
21st Jun 20237:00 amRNSOption Exercise, Admission and Total Voting Rights
13th Jun 20233:50 pmRNSResult of 2023 AGM
19th May 20237:00 amRNS2022 Annual Report and Notice of 2023 AGM
28th Mar 20237:00 amRNS2022 Preliminary Results
26th Jan 20237:00 amRNSTrading Update and Notice of Full Year Results
21st Dec 20223:43 pmRNSNotification of Major Holding
21st Nov 20223:39 pmRNSNotification of Major Holding
14th Nov 20227:00 amRNSChange of Registered Office
20th Oct 20227:34 amRNSCorrective announcement - H1 2022 Interim Results
27th Sep 20227:00 amRNSInterim results for six months ended 30 June 2022
26th Jul 20227:00 amRNSH1 Trading Update and Notice of Interim Results
7th Jun 20225:11 pmRNSResult of 2022 AGM and changes to Board Committees
12th May 20227:00 amRNS2021 Annual Report and Notice of 2022 AGM
3rd May 20227:00 amRNSChanges to Board of Directors
29th Apr 20222:19 pmRNSGrant of options and PDMR Dealing
12th Apr 20221:40 pmRNSNotification of Major Holding
29th Mar 20227:00 amRNSFull year results 2021
24th Mar 20227:00 amRNSAnimalcare and Orthros form VHH R&D collaboration
10th Feb 20222:46 pmRNSAppointment of Non-Executive Director
25th Jan 20227:00 amRNSTrading Update & Notice of Full Year Results
8th Nov 20211:27 pmRNSGrant of options
26th Oct 20219:27 amRNSNotification of Major Holding
5th Oct 20213:22 pmRNSNotification of Major Holding
28th Sep 20217:00 amRNSInterim Results H1 2021
16th Sep 202110:46 amRNSNotification of Major Holding
9th Sep 20211:44 pmRNSNotification of Major Holding
2nd Aug 20217:00 amRNSNotification of Total Voting Rights
30th Jul 202112:00 pmRNSNotification of Major Holding
22nd Jul 20217:00 amRNSHalf Year Trading Update and Notice of Results
15th Jul 20214:11 pmRNSNotification of Major Holding
15th Jul 20217:00 amRNSDirector/PDMR Notification
12th Jul 20214:15 pmRNSNotification of Major Holding
12th Jul 20214:00 pmRNSNotification of Major Holding
12th Jul 20213:35 pmRNSNotification of Major Holding
12th Jul 202111:04 amRNSNotification of Major Holding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.